IL17A and Stroke: Treatment with DS2 significantly decreased circulating IL-6 (0.1 mg/kg, P < 0.01; 1 and 4 mg/kg, P < 0.05), IL-17 and TNF-α levels (P < 0.05 and P < 0.001, respectively following treatment) at 3-days post-stroke.